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MicroRNAs (miRNAs) are endogenous short non-coding RNAs that regulate most of
important cellular processes by inhibiting gene expression through the post-transcriptional
repression of their target mRNAs. In kidneys, miRNAs have been associated in
renal development, homeostasis, and physiological functions. Results from clinical and
experimental animal studies demonstrate that miRNAs play essential roles in the
pathogenesis of various renal diseases. Chronic kidney diseases (CKD) is characterized by
renal fibrosis. Transforming growth factor beta (TGF-β) is recognized as a major mediator of
renal fibrosis because it is able to stimulate the accumulation of extracellular matrix (ECM)
proteins to impair normal kidney function. Recently, emerging evidence demonstrate the
relationship between TGF-β signaling and miRNAs expression during renal diseases. TGF-β
regulates expression of several microRNAs, such as miR-21, miR-192, miR-200, miR-433,
and miR-29. MiR-21, miR-192, and miR-433 which are positively induced by TGF-β signaling
play a pathological role in kidney diseases. In contrast, members in both miR-29 and
miR-200 families which are inhibited by TGF-β signaling protect kidneys from renal
fibrosis by suppressing the deposition of ECM and preventing epithelial-to-mesenchymal
transition, respectively. Clinically, the presence of miRNAs in blood and urine has been
examined to be early biomarkers for detecting renal diseases. From experimental animal
studies of CKD, targeting microRNAs also provides evidence about therapeutic potential
of miRNAs during renal diseases. Now, it comes to the stage to examine the exact
mechanisms of miRNAs during the initiation and progression of renal diseases. Therefore,
determining the function of miRNAs in renal fibrosis may facilitate the development of
both early diagnosis and treatment of renal diseases.
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INTRODUCTION
MicroRNAs (miRNAs) are small, endogenous, non-coding RNAs
that regulate various cellular processes such as death, differenti-
ation, proliferation, metabolism, and pathophysiology of many
diseases via the regulation of target gene expression. During
recent decades, the understandings of miRNAs in molecular
mechanisms on various disease processes are expanding rapidly.
In the kidney diseases, miRNAs also play a key role in renal
fibrosis.
MiRNAs bind to their respective target mRNAs and recruit
the RNA-induced silencing complex (RISC). There are multiple
steps of the biogenesis of miRNAs. Firstly, after having tran-
scribed by RNA polymerase II or RNA polymerase III as long
stem-loop primary miRNA (Pri-miR) in the nucleus, the Pri-miR
is then cleaved into a double-stranded shorter miRNA precur-
sor (Pre-miR) by RNase III enzyme Drosha and its partner
DGCR8 (DiGeorge syndrome critical region 8) (Lee et al., 2003;
Gregory et al., 2004). These Pre-miR will next be exported into
the cytoplasm by the Ran-GTP and Exportin-5 (Du and Zamore,
2005). Pre-miR is further cleaved into the mature form, a 20–
22 base pairs (bp) double-stranded RNA, in the cytoplasm by
another RNase III enzyme Dicer. This mature miRNA-miRNA
duplex is unwound and the functional strand (“guide strand”)
is loaded onto the RISC (Filipowicz, 2005). The mature miRNA
induces the RISC complex to bind to the 3′ untranslated region
(3′ UTR) of a target messenger RNA (mRNA). This will result in
post-transcriptional gene silencing by mRNA degradation or by
translation inhibition. Therefore, miRNAs is able to suppress tar-
get gene expression by mRNA degradation, translation inhibition
or transcriptional inhibition.
Early studies by microarray assays demonstrate that the abun-
dance of miR-192, -194, -204, -215, and -216 are high in the
kidney when compared with other organs (Sun et al., 2004; Tian
et al., 2008). These studies suggest the potential role of miRNAs
in kidney function. So far, more and more miRNAs have been
described in the development, hemostasis and diseases in the kid-
ney (Kato et al., 2009; Li et al., 2010; Bhatt et al., 2011; Lorenzen
et al., 2011). As many comprehensive reviews about the biogen-
esis of miRNAs and the role of miRNAs in normal kidney have
been published (Du and Zamore, 2005; Filipowicz, 2005; Saal and
Harvey, 2009; Wessely et al., 2010; Bhatt et al., 2011; Lorenzen
et al., 2011; Chung et al., 2013b; Li et al., 2014), this review will
focus on recent novel findings into the implications for miRNAs
in renal fibrosis.
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ROLE OF TGF-β SIGNALING IN RENAL FIBROSIS
Renal fibrosis is the common feature of chronic kidney disease
(CKD) progressing to end-stage renal failure. Renal fibrosis is
generally characterized either by interstitial extracellular matrix
(ECM), or myofibroblast accumulation, and destruction of renal
tubules (Bottinger, 2007; Liu, 2011). Transforming growth factor-
beta (TGF-β) is the well-known master cytokine/growth fac-
tor in fibrosis (Roberts, 1998; Wang et al., 2005; Meng et al.,
2010, 2012a,b; Lan and Chung, 2011) (Figure 1). Smad2 and
Smad3 are the important downstream mediators of TGF-β sig-
naling (Massague and Chen, 2000; Miyazono, 2000; Chung et al.,
2010b; Zhou et al., 2010a; Chen et al., 2011; Li et al., 2013b;
Meng et al., 2013). During fibrosis, TGF-β is capable of induc-
ing many fibrogenic genes, such as ECM proteins, via Smad2,
Smad3, or mitogen-activated protein kinases (MAPKs) (Hoffman
et al., 1998; Schnaper et al., 2003; Chung et al., 2009). Recent
studies show that TGF-β also regulates several miRNAs dur-
ing renal fibrosis. TGF-β1 induces miR-21, miR-192, miR-491-
5p, miR-382, miR-377, miR-214, and miR-433, but suppresses
the miR-29 and miR-200 families (Kriegel et al., 2010, 2012a;
Kantharidis et al., 2011; Lan and Chung, 2012; Chung et al.,
2013a) (Table 1). All these TGF-β-regulated miRNAs have been
shown to participate in the events during renal fibrosis (Figure 1).
Furthermore, expression of thesemiRNAs is altered when the kid-
neys are injured in the experimental mouse models of renal injury
(Kantharidis et al., 2011; Lan and Chung, 2012; Chung et al.,
2013a), suggesting that they play essential roles in TGF-β-induced
fibrosis. In this review, we will discuss the recent findings of five
groups of TGF-β-regulated miRNAs, including miR-21, miR-29,
miR-192, miR-200, and miR-433 because they have been shown
to modulate TGF-β-induced renal fibrosis. MiR-21, miR-192, and
miR-433 promote fibrosis while miR-29 and miR-200 families
inhibit fibrosis.
MICRORNAs IN TGF-β-INDUCED RENAL FIBROSIS
MiR-29
Three members of the miR-29 family are encoded from two dis-
tinct genomic loci in both human and rodent genomes (Kriegel
et al., 2012b). All miR-29 members have the identical seed bind-
ing sequence and they all bind to the identical set of target
genes (Kriegel et al., 2012b). Findings from clinical studies and
experimental models suggest the anti-fibrotic effects of miR-29.
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FIGURE 1 | Mechanisms of TGF-β-regulated miRNAs in renal fibrosis.
TGF-β promotes fibrosis by inducing miR-21, miR-433, and miR-192 but
suppressing miR-29 and miR-200 during renal injury. miR-192, miR-433, and
miR-21 play a pathological role in kidney fibrosis through a feed-forward loop
to amplify TGF-β signaling and promote fibrosis. In contrast, members
in miR-29 and miR-200 families play a protective role in renal fibrosis
by inhibiting the deposition of extracellular matrix and preventing
epithelial-to-mesenchymal transition (EMT), respectively.
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Table 1 | Roles of microRNAs in animal models of kidney diseases.
microRNA Mouse model of kidney diseases Pathological output References
miRNAs WHICH ARE INDUCED BY TGF-β
miR-21 UUO, ISI, DN in db/db mice Fibrosis and inflammation Zhong et al., 2011, 2013; Chau et al., 2012
miR-192 UUO, STZ induced DN, DN in db/db mice Fibrosis and EMT Kato et al., 2007; Chung et al., 2010a; Putta et al., 2012
miR-216a STZ induced DN, DN in db/db mice Increases col1a2 expression Kato et al., 2010
miR-377 Spontaneous and STZ induced DN Fibronectin expression Wang et al., 2008
miR-491-5p UUO (rat) Induces Par-3 degradation Zhou et al., 2010b
miR-382 UUO Suppresses E-cadherin Kriegel et al., 2012a
miR-433 UUO Fibrosis, polyamine depletion Li et al., 2013a
miR-29a,b,c UUO, DN in db/db mice Fibrosis Du et al., 2010; Qin et al., 2011; Chen et al., 2014; Lin
et al., 2014
miR-200a,b,c,
miR-141,
miR-429
UUO
STZ induced DN, adenine-induced
EMT Oba et al., 2010; Wang et al., 2011; Xiong et al., 2012
EMT, epithelial-to-mesenchymal transition; DN, diabetic nephropathy; ISIS, ischemia reperfusion injury; STZ, streptozotocin; UUO, Unilateral Ureteral Obstruction.
Abundance of miR-29s is always high in the kidney, lung, and
heart (Kriegel et al., 2012b). However, their abundance is greatly
reduced in animal models and human samples of fibrotic diseases
in heart, lung, and kidney (van Rooij et al., 2008; Qin et al., 2011;
Xiao et al., 2012; Zhang et al., 2014).
By employing microarrays and real-time PCR assays in the
mouse model of unilateral ureteral obstruction (UUO), abun-
dance of miR-29a, -29b, and -29c is substantially decreased in the
fibrotic kidney of UUO wild-type mice but significantly induced
in Smad3 knockout (KO) mice in which renal fibrosis was inhib-
ited (Qin et al., 2011). This negative relationship of miR-29 in
TGF-β-dependent fibrosis is further confirmed by the reduced
expression of miR-29a and miR-29b in renal TECs, lung, and car-
diac fibroblasts after treatment of TGF-β1 (van Rooij et al., 2008;
Qin et al., 2011; Xiao et al., 2012).
Consistent with the results in heart that suppression of miR-
29b increases the levels of fibrotic markers (van Rooij et al., 2008;
Ye et al., 2010; Zhang et al., 2014), overexpression of miR-29
reduces but inhibition of miR-29 enhances abundance of fibrotic
markers in mouse embryonic fibroblasts (MEF) and TECs under
diabetic condition, salt-induced hypertensive conditions, or after
TGF-β treatment, confirming the anti-fibrotic influence of miR-
29 (Du et al., 2010; Liu et al., 2010b; Qin et al., 2011; Chen
et al., 2014) (Figure 1). These reults are further confirmed by
mouse models of unilateral ureteral obstruction and diabetic
nephropathies (Qin et al., 2011; Chen et al., 2014). Delivery of
miR-29b gene either before or after established obstructive and
diabetic nephropathies effectively suppresses the progression of
renal fibrosis. The ability to inhibit TGF-β-mediated deposition
of ECM by miR-29 may be mechanism of how miR-29 protects
kidney from fibrosis because more than 20 different ECM-related
genes are predicted to be miR-29 targets and some of them are
positively regulated by TGF-β signaling (van Rooij et al., 2008).
A recent study demonstrates that increasing miR-29a action also
protects against diabetic podocytopathy by suppressing HDAC4
signaling, nephrin ubiquitination, and urinary nephrin excretion
associated with diabetes and restoring nephrin acetylation (Lin
et al., 2014). In conclusion, miR-29 is a downstream inhibitor of
TGF-β-mediated fibrosis and may have therapeutic potential for
diseases involving fibrosis.
MiR-200
The miR-200 family includes miR-200a, -200b, -200c, -429, and -
141. This family is known to maintain epithelial differentiation
(Howe et al., 2012) because they were firstly discovered by their
ability to restore an epithelial phenotype in breast cancer cell
lines by inhibiting ZEB1 and ZEB2, the E-cadherin transcrip-
tional repressors (Burk et al., 2008; Gregory et al., 2008; Korpal
et al., 2008; Park et al., 2008) (Figure 1). During obstructive
and diabetic nephropathy, abundance of miR-200a and miR-141
are reduced in the fibrotic kidneys (Wang et al., 2011; Xiong
et al., 2012). These findings are confirmed by in vitro studies
that abundance of the miR-200 family in TECs is reduced in a
TGF-β/Smad-dependent manner (Wang et al., 2011; Xiong et al.,
2012). However, opposite results are shown in another study that
renal expression of miR-200s is elevated in the mouse model of
UUO (Oba et al., 2010). However, the differences of miR-200
expression in these mouse models of kidney diseases are possi-
bly due to the differences in the origin of cell lines examined,
the treatments performed, and the use of different animal models
between studies. Side by side comparison of these mouse models
and cell culture studies should be performed to understand the
exact mechanism. In spite of the difference of miR-200 expres-
sion in fibrotic kidneys, the anti-fibrotic role of miR-200 family
is confirmed by gene delivery of miR-200b in fibrotic kidney. A
single injection of miR-200b precursor is sufficient to inhibit the
up-regulation of collagens and fibronectin in obstructed kidneys
(Oba et al., 2010).
MiR-21
MiR-21 is one of the first microRNAs to be described as an
oncomir because it is associated in the genesis and progression
of human cancers (Jazbutyte and Thum, 2010). MiR-21 expres-
sion is closely related to fibrosis and it is up-regulated by TGF-β 1
(Zavadil et al., 2007; Davis et al., 2008, 2010). The first report of
miR-21 in fibrosis is firstly shown in heart failure (Thum et al.,
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2008). Its expression is induced in cardiac fibroblasts of the fail-
ing hearts and delivery of miR-21 antagomir into a mouse model
of cardiac hypertrophy inhibits interstitial fibrosis and restores the
cardiac function (Thum et al., 2008). Similarly, elevation of miR-
21 expression is found in the patients with idiopathic pulmonary
fibrosis and in mice with bleomycin-induced lung fibrosis (Liu
et al., 2010a). Suppressing miR-21 by antisense oligonucleotides
inhibits lung fibrosis in mice (Liu et al., 2010a).
Although the abundance of miR-21 is low in normal kid-
neys, its abundance is greatly increased in both patient samples
of kidney diseases and animal models of CKD and acute kid-
ney injury (AKI) (Godwin et al., 2010; Zhong et al., 2011, 2013;
Chau et al., 2012; Xu et al., 2012; Wang et al., 2013). From the
studies in mouse models of obstructive and diabetic nephropathy,
high abundance of miR-21 is observed in both tubulointerstitial
and glomerular area where fibrosis happens (Zhong et al., 2011,
2013;Wang et al., 2013). In another study of ischemia-reperfusion
injury, similar elevation of renal miR-21 is also observed (Godwin
et al., 2010; Xu et al., 2012). These results suggest the pathological
role of miR-21 in renal diseases.
Similarly, miR-21 positively regulates expression of ECM and
α-SMA in tubular epithelial cell (TEC) and mesangial cells (MCs)
after treatment of TGF-β1 or under diabetic condition (Zhong
et al., 2011, 2013). In addition, knockdown of miR-21 inhibits but
overexpression of miR-21 in kidney cells enhances renal fibrosis
under diabetic condition or after treatment with TGF-β1 (Zarjou
et al., 2011; Zhong et al., 2011, 2013).
Targeting miR-21 should possess a therapeutic potential to
ameliorate the disease related to fibrosis because inhibition of
miR-21 is effectively to decrease fibrosis in rodent models of
heart, lung, and kidney diseases (Thum et al., 2008; Liu et al.,
2010a; Zhong et al., 2011). In the mouse models of diabetic and
obstructive nephropathy, inhibition of miR-21 also improves kid-
ney function and halts the progression of renal injury (Zhong
et al., 2011, 2013).
The results from miR-21 KO mice further confirm the patho-
logical role of renal fibrosis (Chau et al., 2012). Consistence with
the results of unilateral ureteral obstruction (UUO) and renal
ischemia reperfusion injury (ISI) models, miR-21 gene deficiency
in mice reduces renal fibrosis, tubule atrophy, and P42/P44 MAP
kinase pathway activation in diseased kidneys when compared
with wild type mice (Chau et al., 2012). Furthermore, a neg-
ative relationship between the presence of miR-21 and genes
which are involved in lipid metabolism, fatty acid oxidation, and
redox regulation is found in miR-21 KO kidneys. More interest-
ingly, this study also demonstrate that suppression of peroxisome
proliferator-activated receptor-α (PRAR-α) by miR-21 may be
one of mechanisms of how miR-21 promotes renal fibrosis by
(Figure 1) (Chau et al., 2012).
The investigation of how miR-21 regulates fibrosis is still
ongoing. Results from the studies in cardiac fibrosis show that
Phosphatase and tensin homolog (PTEN) and Sprouty (SPRY) are
two of potential targets of miR-21 (Thum et al., 2008; Roy et al.,
2009) (Figure 1). It is found that miR-21 can suppress PTEN to
activate phosphatidylinositide 3-kinases (PI3K) and Akt activity,
and next increases MMP-2 abundance (Roy et al., 2009). As SPRY
is an inhibitor of Ras/MEK/ERK, suppression of SPRY by miR-21
will activate ERK to promote TGF-β-induce fibrosis (Ding et al.,
2008). In heart, suppression ofmiR-21 reduces ERK-MAPK activ-
ity and interstitial fibrosis (Thum et al., 2008). Recent study on
diabetic nephropathy shows that Smad7 and AKT1 substrate 1
(PRAS40), a negative regulator of Tor complex 1 (TORC1), are
potential targets of miR-21 (Dey et al., 2011; Zhong et al., 2013).
Negative correlation between miR-21 and proinflammatory pro-
grammed cell death 4 (PDCD4) has also been reported in TEC
with induction of ischemia (Godwin et al., 2010). As more and
more miR-21 target genes which are related to fibrosis are found,
further studies should be done to clarify how miR-21 exactly
controls these target genes during renal fibrosis.
MiR-192
As mentioned above, abundance of miR-192 is high in the nor-
mal kidney, as compared with other organs (Sun et al., 2004;
Tian et al., 2008). Pro-fibrotic role of miR-192 has been report
in several studies from rodent models of kidney diseases, and in
both MCs and TECs (Kato et al., 2007; Chung et al., 2010a; Putta
et al., 2012). High abundance of miR-192 is detected in glomeruli
isolated from diabetic mice (Kato et al., 2007). Treatment with
TGF-β or high glucose in MCs and TEC up-regulates miR-192
expression (Kato et al., 2007; Chung et al., 2010a). Suppression
of zinc finger E-box binding homeobox 1/2 (Zeb1/2) expression
by miR-192 may be one of the mechanism of how miR-192 reg-
ulates TGF-β-induced collagen expression in MCs (Kato et al.,
2007) (Figure 1). Similarly, inhibition of miR-192 reduces but
overexpression of miR-192 enhances TGF-β1-induced collagen
accumulation in TEC (Chung et al., 2010a). These results are fur-
ther confirmed by a study in a mouse model of type I diabetes.
An in vivo inhibition of renal miR-192 greatly up-regulates renal
expression of Zeb1/2 and inhibits proteinuria, and expression of
collagen and fibronectin (Putta et al., 2012). The pathological role
of miR-192 in diabetic nephropathy is then supported by the find-
ings in miR-192 KO mice (Deshpande et al., 2013). Deletion of
miR-192 gene in type I diabetic mice reduced albuminuria, pro-
teinuria, renal fibrosis, and hypertrophy as compared to diabetic
wild-type mice (Deshpande et al., 2013). Taken together, these
studies demonstrate a pro-fibrotic role of miR-192 in TGF-β-
dependent renal fibrosis observed in animal models of diabetic
and obstructive nephropathy (Kato et al., 2007; Chung et al.,
2010a; Putta et al., 2012).
However, the reverse is true in human nephropathy (Krupa
et al., 2010; Wang et al., 2010). Remarkably, reduction of miR-192
expression is observed in human TECs after TGF-β1 treatment
or in the human diseased kidneys (Krupa et al., 2010; Wang
et al., 2010). This reduction of miR-192 expression correlates
with tubulointerstitial fibrosis and a low GFR in diabetic patients.
These significant differences inmiR-192 expression in human and
animal models of diabetic nephropathy requires further investi-
gation to identify role and mechanism of miR-192’s action during
renal fibrosis in different species.
MiR-433
Early studies of miR-433 focus on its role in cancer (Jung et al.,
2000; Luo et al., 2009). Recently, miR-433 has been found to be
one of the important components of TGF-β/Smad3 driven renal
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fibrosis (Li et al., 2013a). Similar to miR-21 and miR-192, renal
miR-433 expression is induced after UUO. In vitro, TGF-β pro-
motes fibrosis in TEC by inducing miR-433 expression (Li et al.,
2013a). This induction requires the activation of TGF-β signaling.
In addition, inhibition of miR-433 suppresses but overexpression
of miR-433 enhances TGF-β1-induced collagen matrix accumu-
lation in TEC (Li et al., 2013a). More importantly, suppression of
miR-433 in vivo reduces renal fibrosis and halts the progression
of renal fibrosis in established obstructive nephropathy. Antizyme
inhibitor 1 (Azin1), a protective protein in kidney fibrosis, is
found to be a target of miR-433 that overexpression of Azin1 is
able to suppress expression of fibrotic proteins in TEC (Li et al.,
2013a). As Azin1 promotes polyamine synthesis and polyamine
depletion can activate TGF-β signaling by increasing the expres-
sion levels of TGF-β1, TβRI, and Smad3 (Patel et al., 1998; Liu
et al., 2003), elevation of miR-433 during renal fibrosis forms a
positive feedback loop to amplify TGF-β signaling by suppressing
Azin1 expression.
REGULATION OF FIBROSIS-RELATED microRNAs BY TGF-β
SIGNALING
Although the precise mechanism of how TGF-β signaling reg-
ulates miRNA expression during renal fibrosis is still continu-
ing, recent evidence demonstrates that TGF-β signaling induces
the synthesis of fibrosis-related microRNAs either by increasing
transcription, or by enhancing posttranscriptional processing of
primary miRNA transcript. Davis et al demonstrate that TGF-β
signaling enhances the processing of primary transcripts of some
microRNAs into its active form by the Drosha complex, such
as miR-21 (Davis et al., 2008). Smad3, as one of the receptor-
Smads, physically interacts with the Drosha complex to stimulate
the production of mature miR-21 from the pri-miR-21 transcript
(Figure 1). In addition, a consensus sequence (R-SBE) is found
to be located within the stem region of the primary transcripts
of TGF-β-regulated-miRs (pri-T-miRs) (Davis et al., 2010). The
direct binding between Smads and the R-SBE will initialize the
TGF-β-induced recruitment of Drosha, and DGCR8 to pri-T-
miRs and enhance the processing of pri-T-miRs (Davis et al.,
2010).
Our laboratory demonstrates that TGF-β/Smad3 signaling is
able to regulate the transcription of miR-21, miR-192, miR-433,
and the miR-29 family during renal diseases (Chung et al., 2010a;
Qin et al., 2011; Zhong et al., 2011; Li et al., 2013a) (Figure 1).
These results are further supported by the results from in rodent
models of obstructive and remnant kidney diseases induced in
mice lacking Smad3, Smad7, or having conditional knockout
(KO) for Smad2 or overexpressing renal Smad7 (Chung et al.,
2010a, 2013a; Qin et al., 2011; Zhong et al., 2011). This notion is
firstly supported by the in vitro studies that TGF-β inhibits miR-
29 expression but upregulates the expression of miR-21, -192, and
-433 via the Smad3-dependent mechanism as revealed in MCs
and TECs overexpressing Smad7, or knocking down for Smad2
or Smad3 and in Smad2 or Smad3 KO mouse embryonic fibrob-
lasts (MEF) (Chung et al., 2010a, 2013a; Qin et al., 2011; Zhong
et al., 2011). In addition, we also find that Smad3 physically inter-
acts with Smad-binding site (SBE) located in their promoters to
regulate the expression of these miRNAs (Chung et al., 2010a;
Qin et al., 2011; Zhong et al., 2011; Li et al., 2013a). Binding of
Smad3 on SBE in the promoters can either promote transcription
and post-transcriptional processing of miRNAs, such as miR-21,
-192, and -433, or suppress the transcription, such as miR-29b
(Chung et al., 2010a; Qin et al., 2011; Zhong et al., 2011; Li et al.,
2013a). Furthermore, Smad7, which is an inhibitory Smad, is
able to defend kidneys from fibrosis because it can regulate TGF-
β/Smad3-mediated miRNAs by maintaining renal miR-29b but
inhibiting miR-21, -192, and -433 (Chung et al., 2010a, 2013a;
Lan and Chung, 2012).
In addition, the feedback loop occurs as microRNAs can also
regulate the TGF-β/Smad3 signaling (Figure 1). During renal
injury, TGF-β induces the miR-21 expression and this elevation
of miR-21 suppresses Smad7 expression and, in turn, enhances
the TGF-β signaling (Liu et al., 2010a; Zhong et al., 2013). As
a feed-forward loop, miR-21 may amplify TGF-β signal during
renal injury. MiR-21 promotes renal fibrosis may employ the acti-
vation of ERK/MAP kinase signaling in fibroblasts (Thum et al.,
2008).
In contrast, TGF-β expression can be negatively regulated
by miRNAs. For instance, miR-200a is able to suppress TGF-β
expression. Although both TGF-β1 and TGF-β2 suppress miR-
200a expression in renal cells (Wang et al., 2011), TGF-β2 is also
one of the target genes for miR-200a. Overexpression of miR-200a
inhibits TGF-β2 expression, Smad3 activity, and TGF-β1-induced
fibrosis (Wang et al., 2011). These results reveal a possible feed-
back between TGF-β2 and miR-200a. Similarly, miR-29 is shown
to inhibit TGF-β1 and TGF-β2 (van Rooij et al., 2008; Zhang et al.,
2014). Thus, miR-29 may exert its anti-fibrotic effects through
inhibition of TGF-β signaling. In addition, recent studies also
demonstate that TGF-β1 can be extensively post-transcriptionally
regulated by miR-744 and miR-663 (Tili et al., 2010; Martin et al.,
2011).
In addition, polyamine depletion activates TGF-β signaling
(Patel et al., 1998; Rao et al., 2000; Liu et al., 2003) and our labo-
ratory recently demonstrated that depletion of cellular polyamine
levels by targeting Azin1 with a Smad3-dependent miR-433 exag-
gerates TGF-β-induced renal fibrosis (Li et al., 2013a). Both in
vitro and in vivo studies show that elevated expression of TGF-β1,
TβRI, miR-433, and phosphorylated Smad3 after TGF-β1 treat-
ment is inhibited by overexpressing Azin1 or knocking down
miR-433. This inhibition is accompanied by restoring cellular
polyamine levels. These results support our hypothesis that TGF-
β/Smad3-miR433 signaling mediates renal fibrosis. Other studies
demonstrates that the miRNAs also regulate TGF-β signaling dur-
ing renal fibrosis. For instance, TGF-β receptor 1 (TGF-βR1)
is found to be identified as a target of miR-130b but during
fibrosis, miR-130b is down-regulated by TGF-β1 (Castro et al.,
2014). All these results demonstrate the close relationship and the
complexity between miRNAs and TGF-β-induced renal fibrosis.
CLINICAL APPLICATION OF microRNAs IN KIDNEY
DISEASES
BIOMARKERS
The presence of miRNAs in blood and urine suggests the poten-
tial of miRNAs to be biomarkers of kidney diseases. Recently,
more and more investigations imply the circulating miRNAs
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are potential biomarkers for cancer growth and organ injuries
because miRNAs are stable and tissue specific as well as they can
be identified and quantitated (Velu et al., 2012). The potential of
miRNAs to be biomarkers for kidney diseases has been investi-
gated recently. For example, remarkably high levels of circulating
miR-21 is found in patients with severe interstitial fibrosis and
tubular atrophy (Glowacki et al., 2013). An another study also
shows that a total of 27 microRNAs at significantly different lev-
els are found in urine from the patients at different stages of
diabetic nephropathy (Argyropoulos et al., 2013). Furthermore,
these 27 miRNAs have previously been found to participate into
in signaling pathways of renal fibrosis during diabetic kidney dis-
ease. In addition, urinary levels of miR-29b and -29c are related
to proteinuria and renal function in immunoglobulin A (IgA)
nephropathy while miR-93 levels in urine are closely correlated
with glomerular scarring (Wang et al., 2012). Now it should be
time to search for patterns of these miRNAs that are released into
the blood or urine from by diseased kidneys.
THERAPEUTIC POTENTIAL
MiRNAs should have therapeutic potential of miRNAs in kid-
ney diseases because miRNAs play an essential roles in renal
injury. Furthermore, sequence complementarity between mRNA
and miRNA offers a feasible and specific approach to develop
a miRNA drug that specifically targets gene(s) or miRNA(s)
which have pathologic effect on certain disease. Recent improve-
ments in chemical engineering enable us to develop chemical
modified miRNAs that are stable in the circulation, can freely
move into cells to target specific mRNA or miRNA and silence
it (Lorenzen et al., 2011). Conventional construction of overex-
pression or shRNA plasmids provides an alternative to restore
or suppress miRNA transcription, respectively (Qin et al., 2011;
Zhong et al., 2011). In mouse models of kidney disease, restora-
tion of miR-29 and -200 families, or inhibition of miR-21, -192,
and -433 inhibits renal fibrosis (Oba et al., 2010; Qin et al., 2011;
Zhong et al., 2011, 2013; Putta et al., 2012; Chung et al., 2013a).
Thus, application of miRNAs or their inhibitors provides a novel
and effective therapeutic approach to the treatment of kidney
diseases.
The delivery method and safety are the main concern in
the therapeutic application of miRNAs. So far, systemic delivery
of chemical-engineered oligonucleotides is the most method to
inhibit miRNA function (Lorenzen et al., 2011). One of the pos-
sible drawback it that this method may also suppress the function
of miRNAs in organs other than the diseased one. To overcome it,
specific gene delivery system to limit miRNA expression in spe-
cific organs is also developing (Lan et al., 2003; Xiao et al., 2012).
For example, ultrasound-microbubble-mediated gene transfer
developed has been shown to be able to deliver miRNA over-
expression or knockdown plasmids specifically into the living
kidneys (Lan et al., 2003; Qin et al., 2011; Zhong et al., 2011,
2013; Chung et al., 2013a). For the success gene therapy, it is
also essential to control the transgene expression at the desired
therapeutic levels to minimize the side-effect. To achieve this,
an optimal dosage of miRNAs should be considered and inves-
tigated to avoid any undesirable side-effects caused by over doses
of overexpression or inhibition of miRNA expression.
The risks of off-target effects and non-specific immune
response are also the main concern in miRNA therapy. For
instance, the one of main considerations to apply miR-21 as a
therapeutic agent for fibrotic diseases is that the inhibition of
miR-21 expression will result in an induction of apoptosis (Li
et al., 2009; Godwin et al., 2010; Zhong et al., 2011). Similarly,
strong pro-apoptotic effect of miR-29b may also impede the
development of miR-29b gene therapy as overexpression of
microRNA-29b upregulate cell death of multiple myeloma cells
(Zhang et al., 2011). Therefore, miRNA therapeutics still await for
further improvement on the controllable delivery system specific
for cells and organs.
SUMMARY AND PERSPECTIVES
After the discovery of miRNAs and characterization of their func-
tions in kidney diseases in last two decades, it is still plenty of
room for improving our understanding about the specific role
and mechanism of miRNAs in renal pathophysiology. How to
accurately identify miRNA targets becomes one of the key issues
which hinder our progress of miRNAs in renal research because
the short seed sequence of a miRNA allow it to regulate multiple
target genes. Although target prediction programs provide us a
large number of potential miRNA targets, the overlap among var-
ious algorithms is so minimal that only a small portion of these
targets can be validated experimentally. Even after the conserva-
tion of the 3′ UTR among species is included in the investigation,
the number of targets predicted is far more than those for val-
idation. In addition, the power of miRNAs also relies on their
capability of targeting multiple genes that contribute to a path-
way or phenotype. However, this also introduces the difficulty
to search for real targets of miRNAs. We hope that the advances
in the high-throughput validation and proteomic analysis will
provide a solution to identify miRNA targets.
Another difficulty of miRNA research is to understanding the
regulation of miRNA expression because possibly more than one
mediators or pathways participate in regulating miRNA expres-
sion. For example, within a given miRNA cluster, miRNAs may
show the same pattern of expression but some of cluster members
may provide different expression patterns if they do not follow
the pattern (Khella et al., 2012b). Furthermore, it is common that
somemiRNAsmay be encoded frommore than one genomic loci,
such as miR-29b, with very different promoter contexts (Kriegel
et al., 2012b). How to control the miR-29b expression from 2
genomic loci still awaits for further investigation. In addition,
intronic miRNAs provides an interesting question as they do
not always have the same expression pattern as their host gene
(Baskerville and Bartel, 2005). Furthermore, it is found that both
strands of the miRNA are sometimes coexpressed and they usu-
ally target different sets of genes (Khella et al., 2012a). All these
unsolved questions are required to have further studies to under-
stand the mechanism about how to regulate miRNA expression.
Deep sequencing is becoming a valuable tool to provide us a com-
prehensive view of gene expression patterns and quantification of
transcript levels. This information may assist us to correlate the
expression of miRNAs with the target transcripts.
Finally, microRNAs are vital downstream effectors of TGF-
β-induced renal fibrosis. The further understanding of the role
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and mechanism of miRNAs during TGF-β-induced renal fibro-
sis should provide us a novel and effective strategy to halt disease
progression.
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